Olanzapine Market By Application (Schizophrenia, Bipolar Disorder, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Olanzapine Market

Olanzapine is a class of medications called as atypical second-generation antipsychotics. Olanzapine oral tablets are available as the brand-name drugs such as Zyprexa (oral tablet) and Zyprexa Zydis (disintegrating tablet). It predominantly affects the dopamine and serotonin receptors. As an antagonist, it acts on the mesolimbic pathway's dopamine D2 receptors to prevent dopamine from acting at the post-synaptic receptor.

The olanzapine binds loosely to the receptor and dissociates easily, allowing for normal dopamine neurotransmission. It is used to treat psychosis, including hallucinations, delusions, paranoia, or disordered thought, schizophrenia, and bipolar disorder.

Factors such as increase in the prevalence of schizophrenia drive the growth of the market during olanzapine market analysis. For instance, in January 2022, according to a report of the World Health Organization (WHO), schizophrenia affects approximately 24 million people globally in every year. In addition, rise in the number of geriatric population with schizophrenia drives the growth of the olanzapine market.

Old age people are more prone to mental disorders, such as Alzheimer and dementia. Thus, geriatric population signifies increase in patients of chronic diseases. For instance, according to World Health Organization (WHO), by 2050, the global population of people aged 60 years and older is estimated to reach to 2.1 billion. Moreover, government initiatives for mental illness are expected to boost growth of the global olanzapine market, thus, offering expansion opportunities for market competitors.

Furthermore, rise in prevalence of mental health disorders, such as schizophrenia and bipolar disorder amongst the population is major olanzapine market trends that drive the growth of the market. As per the Anxiety and Depression Association of America, an anxiety disorder is the most common mental illness in the U.S., affecting 40 million adults aged 18 and older, or 18.1% of the population every year. Nearly one-half of those diagnosed with depression are also diagnosed with an anxiety disorder. However, rise in awareness about schizophrenia drugs and increase in acceptability of schizophrenia drugs by medical practitioners contribute toward the growth of the olanzapine market size.

Depending on application, the market is segmented into schizophrenia, bipolar disorder, and others. The schizophrenia segment exhibited highest growth in 2021 during olanzapine market forecast, owing to rise in prevalence of schizophrenia due to change in lifestyle. However, the others segment is projected to register highest CAGR during the forecast period owing to rise in prevalence of depression, Tourette's Syndrome, and anorexia. For instance, according to data published by Centers for Disease Control and Prevention (CDC) in 2022, 44% children reported as having moderate or severe Tourette's Syndrome (TS) in the U.S.

On the basis of route of administration, the olanzapine industry is segmented into oral and parenteral. The oral segment exhibited highest growth in 2021, owing to its advantages such as simplest route, pain free, good patient compliance, and convenient to administer drug. However, the parenteral segment is projected to register highest CAGR during the forecast period, owing to advantages such as rapid absorption of drug and onset action of drug.

On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. The drug stores & retail pharmacies segment dominated the olanzapine market share in 2021, owing to factors such as provide better financial & debt management to patients, which boosts consumers to focus on retail pharmacy stores.  

Moreover, the online providers segment is projected to register a highest CAGR of 3.6% during the forecast period, owing to availability of a variety of antipsychotic drugs, such as olanzapine in online system. In addition, e-commerce platforms are more suitable than pharmacies/retail stores, which helps patients buy products at ease, which further drive the segment growth.

Region-wise, North America registered largest olanzapine market share in 2021, owing to its well-established healthcare infrastructure, surge in adoption of mental healthcare services, increase in geriatric population, and rise in prevalence of mental diseases. In addition, strong presence of key players, such as Alkermes, Apotex Inc., Dr. Reddy’s Laboratories Ltd., and Eli Lilly and Company that provide olanzapine products further drives the market growth in this region.

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to increase in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities.

Key findings of the study

• By application, the schizophrenia segment was highest contributor to the olanzapine industry in 2021. However, the others segment is anticipated to grow at the highest CAGR during the forecast period.

• On the basis of route of administration, the oral segment was dominated the market in 2021. However, the parenteral segment is anticipated to grow at the highest CAGR during the forecast period.

• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.

• Region-wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period. 

Overview

Olanzapine is an atypical antipsychotic drug, primarily used to treat schizophrenia and bipolar disorder. It is available in the form of a tablet, injectable, and a disintegrating tablet. It balances dopamine and serotonin to enhance cognition, mood, and behavior. Olanzapine is used to treat the symptoms of schizophrenia, which is a mental condition that causes disturbed or strange thinking, loss of interest in life, and strong or inappropriate emotions, in adults and teenagers 13 years of age and older. It is also used to treat bipolar disorder, which is a manic-depressive disorder, a condition that produces episodes of mania, sadness, and other abnormal moods, in adults and adolescents 13 years of age and older.

World Health Organization (WHO) has recommended mental health action plan to promote mental health and prevent mental disorders in the member states. In addition, according to the key facts published by the WHO, an estimated 300 million people are affected by depression, and 60 million people are affected by bipolar disorder, across the globe. Anxiety disorders are the most communal psychiatric illnesses affecting children and adults. It is evaluated that 44 million American grown-ups experience ill effects of uneasiness issue. Merely, about one-third of those suffering from an anxiety disorder receive treatment, even though the disorders are highly treatable. Therefore, it is indicated that the market is majorly driven by rise in prevalence of mental disorders.

The growth of global olanzapine market is majorly driven by rise in prevalence of schizophrenia globally. For instance, in January 2022, according to World Health Organization (WHO), schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) globally. In addition, increase in cases of Hospital Acquired Infections (HAI), owing to lack of sanitation and preventive measures, is a major factor responsible for the market growth. Furthermore, rise in the number of mental disorder clinics and improvement in healthcare infrastructure further contribute in the market growth. However, high cost of olanzapine and side effects of olanzapine hinder the market growth. Conversely, rise in product approvals for olanzapine in market by key players and high growth potential in developing economies are anticipated to provide lucrative opportunities to the market players. For instance, in June 2021, Alkermes plc., a global biopharmaceutical company, received U.S. Food and Drug Administration (FDA) for its LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

The olanzapine market is segmented into application, route of administration, distribution channel, and region. On the basis of application, the market is segregated into schizophrenia, bipolar disorders, and others. By route of administration, the market is segmented into oral and parenteral. On the basis of distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global olanzapine market are Alkermes, Apotex Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Torrent Power Ltd, and Viatris Inc.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the olanzapine market analysis from 2021 to 2031 to identify the prevailing olanzapine market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the olanzapine market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global olanzapine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Viatri

Scope of Olanzapine Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Schizophrenia

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Bipolar Disorder

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

4.4 Others

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Oral

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Parenteral

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Drug stores and Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Online Providers

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Application

7.2.3 North America Market size and forecast, by Route of Administration

7.2.4 North America Market size and forecast, by Distribution Channel

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Application

7.2.5.1.3 Market size and forecast, by Route of Administration

7.2.5.1.4 Market size and forecast, by Distribution Channel

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Application

7.2.5.2.3 Market size and forecast, by Route of Administration

7.2.5.2.4 Market size and forecast, by Distribution Channel

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Application

7.2.5.3.3 Market size and forecast, by Route of Administration

7.2.5.3.4 Market size and forecast, by Distribution Channel

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Application

7.3.3 Europe Market size and forecast, by Route of Administration

7.3.4 Europe Market size and forecast, by Distribution Channel

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Application

7.3.5.1.3 Market size and forecast, by Route of Administration

7.3.5.1.4 Market size and forecast, by Distribution Channel

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Application

7.3.5.2.3 Market size and forecast, by Route of Administration

7.3.5.2.4 Market size and forecast, by Distribution Channel

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Application

7.3.5.3.3 Market size and forecast, by Route of Administration

7.3.5.3.4 Market size and forecast, by Distribution Channel

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Application

7.3.5.4.3 Market size and forecast, by Route of Administration

7.3.5.4.4 Market size and forecast, by Distribution Channel

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Application

7.3.5.5.3 Market size and forecast, by Route of Administration

7.3.5.5.4 Market size and forecast, by Distribution Channel

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Application

7.3.5.6.3 Market size and forecast, by Route of Administration

7.3.5.6.4 Market size and forecast, by Distribution Channel

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Application

7.4.3 Asia-Pacific Market size and forecast, by Route of Administration

7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Application

7.4.5.1.3 Market size and forecast, by Route of Administration

7.4.5.1.4 Market size and forecast, by Distribution Channel

7.4.5.2 China

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Application

7.4.5.2.3 Market size and forecast, by Route of Administration

7.4.5.2.4 Market size and forecast, by Distribution Channel

7.4.5.3 India

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Application

7.4.5.3.3 Market size and forecast, by Route of Administration

7.4.5.3.4 Market size and forecast, by Distribution Channel

7.4.5.4 Australia

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Application

7.4.5.4.3 Market size and forecast, by Route of Administration

7.4.5.4.4 Market size and forecast, by Distribution Channel

7.4.5.5 South Korea

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Application

7.4.5.5.3 Market size and forecast, by Route of Administration

7.4.5.5.4 Market size and forecast, by Distribution Channel

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Application

7.4.5.6.3 Market size and forecast, by Route of Administration

7.4.5.6.4 Market size and forecast, by Distribution Channel

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Application

7.5.3 LAMEA Market size and forecast, by Route of Administration

7.5.4 LAMEA Market size and forecast, by Distribution Channel

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Application

7.5.5.1.3 Market size and forecast, by Route of Administration

7.5.5.1.4 Market size and forecast, by Distribution Channel

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Application

7.5.5.2.3 Market size and forecast, by Route of Administration

7.5.5.2.4 Market size and forecast, by Distribution Channel

7.5.5.3 South Africa

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Application

7.5.5.3.3 Market size and forecast, by Route of Administration

7.5.5.3.4 Market size and forecast, by Distribution Channel

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Application

7.5.5.4.3 Market size and forecast, by Route of Administration

7.5.5.4.4 Market size and forecast, by Distribution Channel

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 Alkermes, Inc.

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 apotex inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 Aurobindo Pharma Ltd

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 Eli Lilly and Company

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Dr. Reddy's Laboratories Ltd.

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Sun Pharmaceutical Industries Limited

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Torrent Group

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Teva Pharmaceutical Industries Limited

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 Novartis AG

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Viatris

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 2. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. OLANZAPINE MARKET FOR SCHIZOPHRENIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. OLANZAPINE MARKET FOR BIPOLAR DISORDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. OLANZAPINE MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. OLANZAPINE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 8. GLOBAL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. OLANZAPINE MARKET FOR ORAL, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. OLANZAPINE MARKET FOR ORAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 11. OLANZAPINE MARKET FOR PARENTERAL, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 12. OLANZAPINE MARKET FOR PARENTERAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 13. GLOBAL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 14. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 15. OLANZAPINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 16. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 17. OLANZAPINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. OLANZAPINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 20. OLANZAPINE MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 21. NORTH AMERICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 22. NORTH AMERICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 23. NORTH AMERICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 24. NORTH AMERICA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 25. U.S. OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 26. U.S. OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 27. U.S. OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 28. CANADA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 29. CANADA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 30. CANADA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 31. MEXICO OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 32. MEXICO OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 33. MEXICO OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 34. EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 35. EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 36. EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 37. EUROPE OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 38. GERMANY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 39. GERMANY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 40. GERMANY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 41. FRANCE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 42. FRANCE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 43. FRANCE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 44. UK OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 45. UK OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 46. UK OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 47. ITALY OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 48. ITALY OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 49. ITALY OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 50. SPAIN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 51. SPAIN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 52. SPAIN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 53. REST OF EUROPE OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 54. REST OF EUROPE OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 55. REST OF EUROPE OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 56. ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 57. ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 58. ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 59. ASIA-PACIFIC OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 60. JAPAN OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 61. JAPAN OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 62. JAPAN OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 63. CHINA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 64. CHINA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 65. CHINA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 66. INDIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 67. INDIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 68. INDIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 69. AUSTRALIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 70. AUSTRALIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 71. AUSTRALIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 72. SOUTH KOREA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 73. SOUTH KOREA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 74. SOUTH KOREA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 75. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 76. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 77. REST OF ASIA-PACIFIC OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 78. LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 79. LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 80. LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 81. LAMEA OLANZAPINE MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 82. BRAZIL OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 83. BRAZIL OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 84. BRAZIL OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SAUDI ARABIA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 86. SAUDI ARABIA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 87. SAUDI ARABIA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 88. SOUTH AFRICA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 89. SOUTH AFRICA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 90. SOUTH AFRICA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 91. REST OF LAMEA OLANZAPINE MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 92. REST OF LAMEA OLANZAPINE MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 (REVENUE, $MILLION)

TABLE 93. REST OF LAMEA OLANZAPINE MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 94.ALKERMES, INC.: COMPANY SNAPSHOT

TABLE 95.ALKERMES, INC.: OPERATING SEGMENTS

TABLE 96.ALKERMES, INC.: PRODUCT PORTFOLIO

TABLE 97.ALKERMES, INC.: NET SALES

TABLE 98.ALKERMES, INC.: KEY STRATERGIES

TABLE 99.APOTEX INC.: COMPANY SNAPSHOT

TABLE 100.APOTEX INC.: OPERATING SEGMENTS

TABLE 101.APOTEX INC.: PRODUCT PORTFOLIO

TABLE 102.APOTEX INC.: NET SALES

TABLE 103.APOTEX INC.: KEY STRATERGIES

TABLE 104.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT

TABLE 105.AUROBINDO PHARMA LTD: OPERATING SEGMENTS

TABLE 106.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO

TABLE 107.AUROBINDO PHARMA LTD: NET SALES

TABLE 108.AUROBINDO PHARMA LTD: KEY STRATERGIES

TABLE 109.ELI LILLY AND COMPANY: COMPANY SNAPSHOT

TABLE 110.ELI LILLY AND COMPANY: OPERATING SEGMENTS

TABLE 111.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO

TABLE 112.ELI LILLY AND COMPANY: NET SALES

TABLE 113.ELI LILLY AND COMPANY: KEY STRATERGIES

TABLE 114.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT

TABLE 115.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS

TABLE 116.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO

TABLE 117.DR. REDDY'S LABORATORIES LTD.: NET SALES

TABLE 118.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES

TABLE 119.SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 120.SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 121.SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 122.SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES

TABLE 123.SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 124.TORRENT GROUP: COMPANY SNAPSHOT

TABLE 125.TORRENT GROUP: OPERATING SEGMENTS

TABLE 126.TORRENT GROUP: PRODUCT PORTFOLIO

TABLE 127.TORRENT GROUP: NET SALES

TABLE 128.TORRENT GROUP: KEY STRATERGIES

TABLE 129.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 130.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 131.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 132.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES

TABLE 133.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 134.NOVARTIS AG: COMPANY SNAPSHOT

TABLE 135.NOVARTIS AG: OPERATING SEGMENTS

TABLE 136.NOVARTIS AG: PRODUCT PORTFOLIO

TABLE 137.NOVARTIS AG: NET SALES

TABLE 138.NOVARTIS AG: KEY STRATERGIES

TABLE 139.VIATRIS: COMPANY SNAPSHOT

TABLE 140.VIATRIS: OPERATING SEGMENTS

TABLE 141.VIATRIS: PRODUCT PORTFOLIO

TABLE 142.VIATRIS: NET SALES

TABLE 143.VIATRIS: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.OLANZAPINE MARKET SEGMENTATION

FIGURE 2.OLANZAPINE MARKET,2021-2031

FIGURE 3.OLANZAPINE MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.OLANZAPINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.OLANZAPINE MARKET,BY APPLICATION,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF SCHIZOPHRENIA OLANZAPINE MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BIPOLAR DISORDER OLANZAPINE MARKET,2021-2031(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS OLANZAPINE MARKET,2021-2031(%)

FIGURE 16.OLANZAPINE MARKET,BY ROUTE OF ADMINISTRATION,2021(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ORAL OLANZAPINE MARKET,2021-2031(%)

FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PARENTERAL OLANZAPINE MARKET,2021-2031(%)

FIGURE 19.OLANZAPINE MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES OLANZAPINE MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES OLANZAPINE MARKET,2021-2031(%)

FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS OLANZAPINE MARKET,2021-2031(%)

FIGURE 23.OLANZAPINE MARKET BY REGION,2021

FIGURE 24.U.S. OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 25.CANADA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 26.MEXICO OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 27.GERMANY OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 28.FRANCE OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 29.UK OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 30.ITALY OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 31.SPAIN OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 32.REST OF EUROPE OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 33.JAPAN OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 34.CHINA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 35.INDIA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 36.AUSTRALIA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 37.SOUTH KOREA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 38.REST OF ASIA-PACIFIC OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 39.BRAZIL OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 40.SAUDI ARABIA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 41.SOUTH AFRICA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 42.REST OF LAMEA OLANZAPINE MARKET,2021-2031($MILLION)

FIGURE 43. TOP WINNING STRATEGIES, BY YEAR

FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 47.COMPETITIVE DASHBOARD

FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 49.ALKERMES, INC..: NET SALES ($MILLION)

FIGURE 50.APOTEX INC..: NET SALES ($MILLION)

FIGURE 51.AUROBINDO PHARMA LTD.: NET SALES ($MILLION)

FIGURE 52.ELI LILLY AND COMPANY.: NET SALES ($MILLION)

FIGURE 53.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)

FIGURE 54.SUN PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)

FIGURE 55.TORRENT GROUP.: NET SALES ($MILLION)

FIGURE 56.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)

FIGURE 57.NOVARTIS AG.: NET SALES ($MILLION)

FIGURE 58.VIATRIS.: NET SALES ($MILLION